BR112015025172A2 - composição farmacêutica - Google Patents

composição farmacêutica

Info

Publication number
BR112015025172A2
BR112015025172A2 BR112015025172A BR112015025172A BR112015025172A2 BR 112015025172 A2 BR112015025172 A2 BR 112015025172A2 BR 112015025172 A BR112015025172 A BR 112015025172A BR 112015025172 A BR112015025172 A BR 112015025172A BR 112015025172 A2 BR112015025172 A2 BR 112015025172A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
dosage forms
diethylene glycol
monoethyl ether
glycol monoethyl
Prior art date
Application number
BR112015025172A
Other languages
English (en)
Inventor
Shantilal Patel Dinesh
Glovindlal Patel Madhavlal
Dinesh Patel Sachin
Prabhudas Kurani Shashikant
Original Assignee
Themis Medicare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51263451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015025172(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Themis Medicare Ltd filed Critical Themis Medicare Ltd
Publication of BR112015025172A2 publication Critical patent/BR112015025172A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “composição farmacêutica” a presente invenção refere-se a composições farmacêuticas de vários agentes farmacêuticos ativos, em especial ingrediente ativos liofílicos e hidrófilos contendo éter monoetílico de dietileno glicol ou outros derivados de alquila do mesmo como um veículo primário e/ou a composições farmacêuticas que utilizam éter monoetílico de dietileno glicol ou outros derivados de alquila do mesmo como um veículo primário ou como um sistema de solvente na preparação das referidas composições farmacêuticas. as composições farmacêuticas da presente invenção são seguras, não tóxicas, exibem maior estabilidade física comparada a formulações convencionais contendo os referidos agentes farmacêuticos ativos e são adequados para uso como injetáveis para a administração intravenosa e intramuscular, assim como para uso como uma solução/líquido pré-formado para preencher em e preparação de cápsulas, tabletes, sprays nasais, gargarejos, aplicações dérmicas, géis, tópicos, forma de dosagem oral líquidas e outras formas de dosagem. ?? ?? ?? ?? 1/1
BR112015025172A 2013-04-02 2014-04-02 composição farmacêutica BR112015025172A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1287MU2013 IN2013MU01287A (pt) 2013-04-02 2014-04-02
PCT/IN2014/000207 WO2014178065A1 (en) 2013-04-02 2014-04-02 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives

Publications (1)

Publication Number Publication Date
BR112015025172A2 true BR112015025172A2 (pt) 2017-07-18

Family

ID=51263451

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025172A BR112015025172A2 (pt) 2013-04-02 2014-04-02 composição farmacêutica

Country Status (17)

Country Link
US (2) US9827315B2 (pt)
JP (1) JP6272454B2 (pt)
KR (2) KR20170110728A (pt)
CN (1) CN105392469A (pt)
AU (1) AU2014261009B2 (pt)
BR (1) BR112015025172A2 (pt)
CA (1) CA2908571C (pt)
HK (1) HK1222549A1 (pt)
IN (1) IN2013MU01287A (pt)
MA (1) MA38544A1 (pt)
MX (1) MX2015013785A (pt)
PE (1) PE20151663A1 (pt)
PH (1) PH12015502290B1 (pt)
SA (1) SA515361262B1 (pt)
SG (1) SG11201508006SA (pt)
UA (1) UA119324C2 (pt)
WO (1) WO2014178065A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US9713621B2 (en) * 2012-01-19 2017-07-25 Edward Lichten Treatment of endometriosis
CA2871778C (en) 2012-05-03 2022-09-13 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102154880B1 (ko) 2012-05-03 2020-09-10 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
CN104546775B (zh) * 2015-02-03 2017-08-25 山东新时代药业有限公司 一种阿托伐他汀钙片剂
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017002030A1 (en) * 2015-06-30 2017-01-05 Leiutis Pharmaceuticals Pvt Ltd Stable liquid formulations of melphalan
US20180289721A1 (en) * 2015-10-13 2018-10-11 Themis Medicare Limited Fulvestrant compositions
KR101634382B1 (ko) * 2015-10-20 2016-06-28 미래제약 주식회사 타다라필 경구용 액제
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US20180325813A1 (en) * 2015-11-07 2018-11-15 Ftf Pharma Private Limited Oral solution of ace inhibitors
WO2017132243A1 (en) * 2016-01-29 2017-08-03 Cuda Anesthetics, Llc Aqueous pharmaceutical formulation comprising propofol
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
KR20190005871A (ko) * 2016-04-13 2019-01-16 노틱 홀딩스 잉크. 안정한 니모디핀 비경구 제제
US10092553B2 (en) 2016-04-13 2018-10-09 Nortic Holdings Inc. Stable nimodipine parenteral formulation
KR20190109604A (ko) * 2016-05-06 2019-09-25 해로우 헬스 인코포레이티드 약학적 안과용 조성물 및 그의 제조 방법
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP4295853A3 (en) * 2016-06-28 2024-03-06 Emergent BioDefense Operations Lansing LLC Formulations of brincidofovir
WO2018049184A1 (en) 2016-09-09 2018-03-15 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
FR3057775B1 (fr) * 2016-10-26 2018-11-02 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
BE1024559B1 (nl) * 2017-02-21 2018-04-05 Purna Pharmaceuticals Nv Werkwijze voor het maken van een verstuifbare emulsie omvattende een corticosteroïde, een aminoglycoside en een zuur
CN108721209A (zh) * 2017-04-20 2018-11-02 广东东阳光药业有限公司 一种兽用阿奇霉素注射剂
CN117085022A (zh) 2017-06-02 2023-11-21 Xeris药物公司 抗沉淀的小分子药物制剂
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
CA3072335A1 (en) * 2017-08-09 2019-02-14 Piedmont Animal Health Inc. Therapeutic formulations and uses thereof
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CN110314158A (zh) * 2018-03-22 2019-10-11 深圳澳美制药技术开发有限公司 噻康唑组合物及其制备方法
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
CN109364021A (zh) * 2018-10-26 2019-02-22 山西普德药业有限公司 一种注射用长春西汀
US10799481B1 (en) 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
SG11202113266YA (en) 2019-06-04 2021-12-30 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof
EP3982927A1 (en) 2019-06-14 2022-04-20 Propella Therapeutics, Inc. Topical acyclovir formulations and uses thereof
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
US11135208B2 (en) 2019-08-12 2021-10-05 American Regent, Inc. 1,4-dihydropyridine compositions, methods of making and use
JP2023501207A (ja) * 2019-11-01 2023-01-18 ピードモント アニマル ヘルス インコーポレイテッド 治療用製剤およびその使用
US20230073803A1 (en) * 2019-12-16 2023-03-09 Themis Medicare Limited Pharmaceutical composition of cyclooxygenase - 2 inhibitors
CN111632029B (zh) * 2020-06-28 2021-05-07 江苏吴中医药集团有限公司 一种美索巴莫注射液及其制备方法
CN112315905B (zh) * 2020-12-07 2021-11-30 安徽海洋药业有限公司 一种蒿甲醚注射液及其制备方法
CN112370422B (zh) * 2020-12-09 2023-03-03 南京联智医药科技有限公司 取代的β-环糊精稳定的盐酸屈他维林注射液及其制备方法
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN113004301B (zh) * 2021-03-11 2022-02-18 广西师范大学 一种青蒿琥酯基-二苯基脲衍生物ars-dpu及其制备方法与应用
CN113069527B (zh) * 2021-04-20 2022-03-18 北京华睿鼎信科技有限公司 一种具有解酒保肝功能的组合物及其制备方法
CN115702936A (zh) * 2021-08-13 2023-02-17 杭州中美华东制药有限公司 一种芦可替尼组合物及其用途
FR3128874A1 (fr) * 2021-11-09 2023-05-12 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
EP4233837A1 (en) * 2022-02-24 2023-08-30 CellAct Pharma GmbH Solid and oral etoposide toniribate compositions
US20240108609A1 (en) 2022-09-15 2024-04-04 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
FR2756736B1 (fr) * 1996-12-05 1999-03-05 Sanofi Sa Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
KR100382347B1 (ko) * 2000-10-30 2003-05-01 에스케이케미칼주식회사 시트상 자기발열체 및 이의 제조방법
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
US6551615B1 (en) * 2001-10-18 2003-04-22 M/S. Strides Arcolab Limited Dexibuprofen-containing soft gelatin capsules and process for preparing the same
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
JP2006513149A (ja) * 2002-05-17 2006-04-20 ニュー ホライゾンズ ディアグノスティックス コーポレイション Ｂａｃｉｌｌｕｓａｎｔｈｒａｃｉｓを迅速かつ特異的に検出および殺滅するファージ関連溶菌酵素の同定
US6967194B1 (en) * 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
WO2006067138A2 (en) 2004-12-21 2006-06-29 Intervet International B.V. Injectable veterinary composition
US20070149442A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Non-hygroscopic compositions of enterostatin
US20110020440A1 (en) * 2007-11-19 2011-01-27 Cadila Pharmaceuticals Limited Stable solutions of sparingly soluble actives
US8128913B1 (en) * 2007-12-06 2012-03-06 Skinvisible Pharmaceuticals, Inc. Sunscreen composition with enhanced UV-A absorber stability and methods
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
CN102065893A (zh) * 2008-04-15 2011-05-18 萨可德公司 Lfa-1拮抗剂向胃肠系统的递送
KR101096429B1 (ko) * 2008-07-18 2011-12-20 한국유나이티드제약 주식회사 안정성이 향상된 아세클로페낙의 경구용 연질캅셀제
US20100215726A1 (en) * 2009-02-25 2010-08-26 Peter Thomas Roth Compositions for Diminishing the Appearance of Wrinkles
WO2010129686A1 (en) * 2009-05-05 2010-11-11 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
EP2473161B1 (en) * 2009-08-31 2017-05-17 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
US9737478B2 (en) * 2009-09-28 2017-08-22 National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR) Treatment of malaria
CN102711835B (zh) * 2009-11-27 2014-12-10 努沃研究股份有限公司 局部布洛芬制剂
WO2011149645A1 (en) * 2010-05-28 2011-12-01 Nuvo Research Inc. Topical etoricoxib formulation
US8747818B1 (en) * 2011-02-07 2014-06-10 Dennis Gross Self-tanning compositions
EA026697B1 (ru) * 2011-05-03 2017-05-31 Апониа Лабораториз, Инк. Трансдермальные композиции ибупрофена и способы их применения
CA2877083C (en) * 2012-06-27 2020-10-06 Medincell Biodegradable drug delivery for hydrophobic compositions

Also Published As

Publication number Publication date
KR20150126067A (ko) 2015-11-10
WO2014178065A1 (en) 2014-11-06
JP2016515609A (ja) 2016-05-30
MA38544A1 (fr) 2017-03-31
US20140296191A1 (en) 2014-10-02
US10940205B2 (en) 2021-03-09
CN105392469A (zh) 2016-03-09
SG11201508006SA (en) 2015-10-29
PE20151663A1 (es) 2015-12-03
SA515361262B1 (ar) 2018-08-18
UA119324C2 (uk) 2019-06-10
US9827315B2 (en) 2017-11-28
US20180071390A1 (en) 2018-03-15
KR20170110728A (ko) 2017-10-11
AU2014261009B2 (en) 2017-05-04
PH12015502290A1 (en) 2016-02-01
HK1222549A1 (zh) 2017-07-07
PH12015502290B1 (en) 2016-02-01
CA2908571A1 (en) 2014-11-06
IN2013MU01287A (pt) 2015-05-29
AU2014261009A1 (en) 2015-10-29
JP6272454B2 (ja) 2018-01-31
CA2908571C (en) 2018-11-06
MX2015013785A (es) 2016-08-19
KR101875263B1 (ko) 2018-07-05

Similar Documents

Publication Publication Date Title
BR112015025172A2 (pt) composição farmacêutica
BR112018008880A8 (pt) composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112013008005A2 (pt) composição farmacêutica kpiquida pronta para uso para adminidtração parental a um indivíduo
BR112015018838A2 (pt) estabilidade melhorada de novas composições líquidas
BR112014010590A2 (pt) 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose
CL2013003365A1 (es) Formulacion farmaceutica que comprende diacilglicerol y/o tocoferol, fosfatidilcolina, solvente mono-alcoholico organico biocompatible que comprende etanol, solvente polar, y un analogo de somatostatina como principio activo; proceso para prepararla; kit farmaceutico; uso en el tratamiento de acromegalia y canceres, entre otros.
BR112014023374A8 (pt) composições farmacêuticas de peptídeos de glp-1, grânulo, processos de produção dos mesmos e seus usos na preparação de medicamentos
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112013031268A2 (pt) "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição".
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
CO2019012814A2 (es) Composición farmacéutica líquida estable
CO6710926A2 (es) Compuestos de n-heteroarilo
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112015027436A8 (pt) composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
ECSP13013095A (es) Composición farmacéutica que comprende fexofenadina
BRPI0815280A2 (pt) medicamento que compreende uma formulação líquida aquosa de g-csf, receptáculo para a administração de medicamentos líquidos, seringa ou ampola, kit para a administração parenteral de g-csf
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол
PE20150632A1 (es) Composicion farmaceutica que tiene fluidez mejorada, agente medicional, y metodo para la produccion y uso del mismo
BR112015014180A8 (pt) composições de gel

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2664 DE 25-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.